{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:21:37Z","timestamp":1792095697099,"version":"4.4.0"},"reference-count":264,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly increases the risk of steatohepatitis and cirrhosis and multiple extrahepatic complications, in particular, cardiometabolic disease, including type 2 diabetes, atherosclerotic cardiovascular disease (CVD), and heart failure, with a significant negative impact on health-related quality of life, becoming a substantial economic burden. Moreover, cardiovascular events represent the leading cause of death in MASLD patients. A timely diagnosis stratifies patient for their risk. It can facilitate early lifestyle changes or pharmacological management of dysmetabolic conditions, thereby slowing disease progression, lowering cardiovascular risk, and preventing CVD and cirrhosis. In this narrative review, we will discuss the current knowledge on MASLD and metabolic dysfunction-associated steatohepatitis (MASH) pathophysiology, emphasizing their systemic nature, the link to CVD, and available and emerging treatment strategies.<\/jats:p>","DOI":"10.3390\/ijms26168081","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:41:45Z","timestamp":1755848505000},"page":"8081","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-117X","authenticated-orcid":false,"given":"Giovanna","family":"Gallo","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Via di Grottarossa 1035\u20131039, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9011-6651","authenticated-orcid":false,"given":"Gabriele","family":"Nalli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Via di Grottarossa 1035\u20131039, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-272X","authenticated-orcid":false,"given":"Francesco","family":"Baratta","sequence":"additional","affiliation":[{"name":"Geriatric Unit, Department of Internal Medicine and Medical Specialties, AOU Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Desideri","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-1959","authenticated-orcid":false,"given":"Carmine","family":"Savoia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Via di Grottarossa 1035\u20131039, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-024-02072-z","article-title":"Liver diseases: Epidemiology, causes, trends and predictions","volume":"10","author":"Gan","year":"2025","journal-title":"Signal Transduct Target Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"109981","DOI":"10.1016\/j.diabres.2022.109981","article-title":"Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis","volume":"190","author":"Ciardullo","year":"2022","journal-title":"Diabetes Res Clin Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between nonalcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhai, M., Liu, Z., Long, J., Zhang, Y., Liu, M., Wang, Y., and Jiang, Y. (2021). The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-84577-z"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dsi23-0010","article-title":"Understanding the burden of nonalcoholic fatty liver disease: Time for action","volume":"37","author":"Younossi","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bansal, B., Lajeunesse-Trempe, F., Keshvani, N., Lavie, C.J., and Pandey, A. (2025). Impact of Metabolic Dysfunction-associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure. Can. J. Cardiol.","DOI":"10.1016\/j.cjca.2025.04.012"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","article-title":"Heritability of hepatic fibrosis and steatosis based on a prospective twin study","volume":"149","author":"Loomba","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-term follow-up of patients with nonalcoholic fatty liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_16","first-page":"1154","article-title":"Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1056\/NEJMoa0907295","article-title":"Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease","volume":"362","author":"Petersen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/hep.1840220616","article-title":"The natural history of nonalcoholic fatty liver: A follow-up study","volume":"22","author":"Teli","year":"1995","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"Pais","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on theAASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity with Progression of Nonalcoholic Fatty Liver Disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.14309\/ajg.0000000000001176","article-title":"Poor outcomes of cirrhosis due to nonalcoholic steatohepatitis compared with hepatitis B after decompensation with ascites","volume":"116","author":"Tan","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Luci, C., Bourinet, M., Leclere, P.S., Anty, R., and Gual, P. (2020). Chronic inflammation in non-alcoholic steatohepatitis: Molecular mechanisms and therapeutic strategies. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.597648"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100192","DOI":"10.1016\/j.jhepr.2020.100192","article-title":"NAFLD and liver transplantation: Disease burden, current management and future challenges","volume":"2","author":"Burra","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","article-title":"Population-based risk factors andresource utilization for HCC: US perspective","volume":"26","author":"Sanyal","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ajg.2011.327","article-title":"Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma","volume":"107","author":"Kawamura","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s10620-016-4085-6","article-title":"Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD","volume":"61","author":"Reeves","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/atm.2017.04.41","article-title":"Type 2 diabetes mellitus and risk of hepatocellular carcinoma: Spotlight on nonalcoholic fatty liver disease","volume":"5","author":"Mantovani","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: A meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.29315","article-title":"Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices","volume":"66","author":"Taylor","year":"2017","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.cgh.2021.02.027","article-title":"MAFLD and cardiovascular events: What does the evidence show?","volume":"19","author":"George","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","article-title":"Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD","volume":"19","author":"Nguyen","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States","volume":"75","author":"Kim","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5009\/gnl210167","article-title":"Innovative target exploration of Nc. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease","volume":"16","author":"Moon","year":"2022","journal-title":"Gut Liver."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/j.1572-0241.2008.02034.x","article-title":"Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study","volume":"103","author":"Dunn","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MEG.0000000000001075","article-title":"Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: A meta-analysis","volume":"30","author":"Zhou","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.3748\/wjg.v29.i25.3999","article-title":"Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis","volume":"29","author":"Pal","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2147\/DMSO.S250699","article-title":"Anti-lipolysis induced by insulin in diverse pathophysiologic conditions of adipose tissue","volume":"13","author":"Zhao","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): A state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1128\/MCB.00422-15","article-title":"The role of PDE3B phosphorylation in the inhibition of lipolysis by insulin","volume":"35","author":"DiPilato","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., and Di Ciaula, A. (2024). Metabolic dysfunction-associated steatotic liver disease: From pathogenesis to current therapeutic options. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115640"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","article-title":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"400","author":"Maccalli","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lu, Q., Tian, X., Wu, H., Huang, J., Li, M., Mei, Z., Zhou, L., Xie, H., and Zheng, S. (2021). Metabolic changes of hepatocytes in NAFLD. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.710420"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ajpath.2023.08.007","article-title":"The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis","volume":"193","author":"Venkatesan","year":"2023","journal-title":"Am. J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, regulation and functions of the unfolded protein response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kim, K.E., Shin, H.J., Ju, Y., Jung, Y., An, H.S., Lee, S.J., Jeong, E.A., Lee, J., Hwang, G.S., and Roh, G.S. (2023). Intermittent fasting attenuates metabolic-dysfunction-associated steatohepatitis by enhancing the hepatic autophagy-lysosome pathway. Nutrients, 15.","DOI":"10.3390\/nu15214574"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/s41467-023-38165-6","article-title":"Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease","volume":"14","author":"Zeng","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e20220681","DOI":"10.1084\/jem.20220681","article-title":"Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH","volume":"220","author":"Itoh","year":"2023","journal-title":"J. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"101238","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5551\/jat.ED247","article-title":"MAFLD and small dense LDL cholesterol: A mechanistic link","volume":"31","author":"Shimabukuro","year":"2024","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3000605231164548","DOI":"10.1177\/03000605231164548","article-title":"Insulin resistance and cardiovascular disease","volume":"51","author":"Kosmas","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Kosmalski, M., Ziolkowska, S., Czarny, P., Szemraj, J., and Pietras, T. (2022). The coexistence of nonalcoholic fatty liver disease and type 2 diabetes mellitus. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051375"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Koutentakis, M., Kucinski, J., Swieczkowski, D., Surma, S., Filipiak, K.J., and Gasecka, A. (2023). The ketogenic effect of SGLT-2 inhibitors\u2014Beneficial or harmful?. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10110465"},{"key":"ref_69","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Cho, I.J., Oh, D.H., Yoo, J., Hwang, Y.C., Ahn, K.J., Chung, H.Y., Jeong, S.W., Moon, J.Y., Lee, S.H., and Lim, S.J. (2021). Allopurinol ameliorates high fructose diet-induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-88872-7"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-13-7","article-title":"Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone","volume":"13","author":"Chai","year":"2014","journal-title":"Lipids Health Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejim.2022.03.025","article-title":"Non-alcoholic fatty liver disease: Identical etiologic factors in patients with type 1 and type 2 diabetes","volume":"100","author":"Westerink","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gut.2010.213553","article-title":"Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: A population-based study","volume":"59","author":"Stepanova","year":"2010","journal-title":"Gut"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.27981","article-title":"Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study","volume":"63","author":"Koehler","year":"2016","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"27078","DOI":"10.1186\/s12933-022-01697-0","article-title":"Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention","volume":"21","author":"Zhou","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"100726","DOI":"10.1016\/j.aohep.2022.100726","article-title":"Abdominal obesity, chronic inflammation and the risk of non-alcoholic fatty liver disease","volume":"28","author":"Zhao","year":"2023","journal-title":"Ann. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gallo, G., Desideri, G., and Savoia, C. (2024). Update on obesity and cardiovascular risk: From pathophysiology to clinical management. Nutrients, 16.","DOI":"10.3390\/nu16162781"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Gutierrez-Cuevas, J., Santos, A., and Armendariz-Borunda, J. (2021). Pathophysiological molecular mechanisms of obesity: A link between MAFLD and NASH with cardiovascular diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111629"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12072-022-10436-2","article-title":"Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States","volume":"17","author":"Dao","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep4.1519","article-title":"Prevalence and profile of nonalcoholic fatty liver disease in lean adults: Systematic review and meta-analysis","volume":"4","author":"Young","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study","volume":"2","author":"Hagstrom","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000000329","article-title":"Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)","volume":"78","author":"Nabi","year":"2023","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1161\/ATVBAHA.114.303035","article-title":"Links between ectopic fat and vascular disease in humans","volume":"34","author":"Lim","year":"2014","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Kozawa, J., and Shimomura, I. (2021). Ectopic fat accumulation in pancreas and heart. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061326"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2021.04.003","article-title":"Pericardial fat and the risk of heart failure","volume":"77","author":"Kenchaiah","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5334\/gh.1078","article-title":"Association of periaortic fat and abdominal visceral fat with coronary artery atherosclerosis in Chinese middle aged and elderly patients undergoing computed tomography coronary angiography","volume":"16","author":"Zhu","year":"2021","journal-title":"Glob. Heart"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"D\u2019Oria, R., Genchi, V.A., Caccioppoli, C., Calderoni, I., Marrano, N., Biondi, G., Borrelli, A., Di Gioia, L., Giorgino, F., and Laviola, L. (2022). Impact of dysfunctional adipose tissue depots on the cardiovascular system. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214296"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2015.05.044","article-title":"Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease","volume":"149","author":"Korf","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis","volume":"155","author":"Musso","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.cmet.2012.03.005","article-title":"Diacylglycerol activation of protein kinase C\u03b5 and hepatic insulin resistance","volume":"15","author":"Jornayvaz","year":"2012","journal-title":"Cell Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1210\/er.2005-0005","article-title":"Adiponectin and adiponectin receptors","volume":"26","author":"Kadowaki","year":"2005","journal-title":"Endocr. Rev."},{"key":"ref_95","first-page":"313","article-title":"Serum adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"59","author":"Polyzos","year":"2010","journal-title":"Metabolism"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Ismaiel, A., and Dumitra\u015fcu, D.L. (2019). Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis\u2014Literature Review. Front. Med., 6.","DOI":"10.3389\/fmed.2019.00202"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jacc.2021.07.042","article-title":"Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review","volume":"78","author":"Montone","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep4.1155","article-title":"Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis","volume":"2","author":"Zhou","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_99","first-page":"19","article-title":"Leptin in immunity: A focus on T cells and dendritic cells","volume":"228","author":"Mancuso","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nri1937","article-title":"Adipocytokines: Mediators linking adipose tissue, inflammation and immunity","volume":"6","author":"Tilg","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI200317797","article-title":"The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice","volume":"112","author":"Xu","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.3567","article-title":"Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failure","volume":"27","author":"Chang","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4093\/dmj.2012.36.4.262","article-title":"GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease","volume":"36","author":"Lee","year":"2012","journal-title":"Diabetes Metab. J."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Yang, K., and Song, M. (2023). New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut\u2013Liver\u2013Heart Crosstalk. Nutrients, 15.","DOI":"10.3390\/nu15183970"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","article-title":"Metabolic-Associated Fatty Liver Disease (MAFLD): A Multisystemic Disease Beyond the Liver","volume":"10","author":"Kaya","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s12072-024-10660-y","article-title":"MAFLD as Part of Systemic Metabolic Dysregulation","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Burger, K., Jung, F., Baumann, A., Brandt, A., Staltner, R., Sanchez, V., and Bergheim, I. (2023). TNF\u03b1 Is a Key Trigger of Inflammation in Diet-Induced Non-Obese MASLD in Mice. Redox Biol., 66.","DOI":"10.1016\/j.redox.2023.102870"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/abbs\/gmv092","article-title":"Excess TNF-\u03b1 in the Blood Activates Monocytes with the Potential to Directly Form Cholesteryl Ester-Laden Cells","volume":"47","author":"Zhu","year":"2015","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Rafaqat, S., Gluscevic, S., Mercantepe, F., Rafaqat, S., and Klisic, A. (2024). Interleukins: Pathogenesis in Non-Alcoholic Fatty Liver Disease. Metabolites, 14.","DOI":"10.3390\/metabo14030153"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Duan, Y., Pan, X., Luo, J., Xiao, X., Li, J., Bestman, P.L., and Luo, M. (2022). Association of Inflammatory Cytokines with Non-Alcoholic Fatty Liver Disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880298"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.molimm.2022.04.003","article-title":"IL-6 Regulates Induction of C-Reactive Protein Gene Expression by Activating STAT3 Isoforms","volume":"146","author":"Ngwa","year":"2022","journal-title":"Mol. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrcardio.2009.55","article-title":"Obesity, inflammation, and atherosclerosis","volume":"6","author":"Rocha","year":"2009","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: A comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., and Singh, B.K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1433857"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Ma, Y., Lee, G., Heo, S.Y., and Roh, Y.S. (2021). Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease. Antioxidants, 11.","DOI":"10.3390\/antiox11010091"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Batty, M., Bennett, M.R., and Yu, E. (2022). The Role of Oxidative Stress in Atherosclerosis. Cells, 11.","DOI":"10.3390\/cells11233843"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jacc.2017.05.035","article-title":"Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series","volume":"70","author":"Camici","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5937\/jomb0-24652","article-title":"The Role of Oxidative Stress in the Development of Obesity and Obesity-Related Metabolic Disorders","volume":"40","author":"Colak","year":"2021","journal-title":"J. Med. Biochem."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Medina-Leyte, D.J., Zepeda-Garcia, O., Dominguez-Perez, M., Gonzalez-Garrido, A., Villarreal-Molina, T., and Jacobo-Albavera, L. (2021). Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083850"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11892-024-01542-6","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Atherosclerosis","volume":"24","year":"2024","journal-title":"Curr. Diab. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Gallo, G., and Savoia, C. (2024). New Insights into Endothelial Dysfunction in Cardiometabolic Diseases: Potential Mechanisms and Clinical Implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052973"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Kruger-Genge, A., Blocki, A., Franke, R.P., and Jung, F. (2019). Vascular Endothelial Cell Biology: An Update. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184411"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Nasiri-Ansari, N., Androutsakos, T., Flessa, C.M., Kyrou, I., Siasos, G., Randeva, H.S., Kassi, E., and Papavassiliou, A.G. (2022). Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells, 11.","DOI":"10.3390\/cells11162511"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e2303259","DOI":"10.1002\/advs.202303259","article-title":"Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications","volume":"10","author":"Andrabi","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4254\/wjh.v7.i3.443","article-title":"Endothelial Dysfunction in Cirrhosis: Role of Inflammation and Oxidative Stress","volume":"7","author":"Vairappan","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1573403X16666200618161942","article-title":"Endothelial Dysfunction and Coronary Vasoreactivity\u2014A Review of the History, Physiology, Diagnostic Techniques, and Clinical Relevance","volume":"17","author":"Gunawardena","year":"2021","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3325\/cmj.2021.62.25","article-title":"Non-Alcoholic Fatty Liver Disease\u2014A Procoagulant Condition?","volume":"62","author":"Forgac","year":"2021","journal-title":"Croat. Med. J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.14218\/JCTH.2021.00268","article-title":"Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications","volume":"10","author":"Ogresta","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Tripodi, A., Lombardi, R., Primignani, M., La Mura, V., Peyvandi, F., and Fracanzani, A.L. (2022). Hypercoagulability in patients with non-alcoholic fatty liver disease (NAFLD): Causes and consequences. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020249"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The Severity of Nonalcoholic Fatty Liver Disease Is Associated with Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.26319","article-title":"Intestinal Microbiota in Patients with Nonalcoholic Fatty Liver Disease","volume":"58","author":"Mouzaki","year":"2013","journal-title":"Hepatology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/liv.12315","article-title":"Toll-Like Receptors and Liver Disease","volume":"34","author":"Kesar","year":"2014","journal-title":"Liver Int."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Mouzaki, M., Wang, A.Y., Bandsma, R., Comelli, E.M., Arendt, B.M., Zhang, L., and Allard, J.P. (2016). Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151829"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2009.09.060","article-title":"The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors","volume":"138","author":"Modica","year":"2010","journal-title":"Gastroenterology."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: The FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Wu, L., Li, J., Feng, J., Ji, J., Yu, Q., Li, Y., Zheng, Y., Dai, W., Wu, J., and Guo, C. (2021). Crosstalk between PPARs and gut microbiota in NAFLD. Biomed. Pharmacother., 136.","DOI":"10.1016\/j.biopha.2021.111255"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Lian, C.Y., Zhai, Z.Z., Li, Z.F., and Wang, L. (2020). High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chem.-Biol. Interact., 330.","DOI":"10.1016\/j.cbi.2020.109199"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Hymel, E., Vlock, E., Fisher, K.W., and Farazi, P.A. (2022). Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0272623"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Montemayor, S., Mascar\u00f3, C.M., Ugarriza, L., Casares, M., Llompart, I., Abete, I., Zulet, M.\u00c1., Mart\u00ednez, J.A., Tur, J.A., and Bouzas, C. (2022). Adherence to Mediterranean Diet and NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study. Nutrients, 14.","DOI":"10.3390\/nu14153186"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Kositamongkol, C., Kanchanasurakit, S., Auttamalang, C., Inchai, N., Kabkaew, T., Kitpark, S., Chaiyakunapruk, N., Duangjai, A., Saokaew, S., and Phisalprapa, P. (2021). Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.786596"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"154439","DOI":"10.1016\/j.metabol.2020.154439","article-title":"Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus","volume":"115","author":"Blomdahl","year":"2021","journal-title":"Metabolism"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1016\/j.cgh.2022.10.039","article-title":"Nonheavy alcohol use associates with liver fibrosis and nonalcoholic steatohepatitis in the framingham heart study","volume":"21","author":"Rice","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_147","unstructured":"GBD 2016 Alcohol Collaborators (2018). Alcohol use and burden for 195 countries and territories, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet, 392, 1015\u20131035."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/hep.22726","article-title":"Ethnic differences in hepatic steatosis: An insulin resistance paradox?","volume":"49","author":"Guerrero","year":"2009","journal-title":"Hepatology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1172\/JCI93465","article-title":"Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis","volume":"127","author":"Caussy","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-126-2-199701150-00008","article-title":"Nonalcoholic steatohepatitis","volume":"126","author":"Sheth","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.dld.2009.03.005","article-title":"Genetic polymorphisms in non-alcoholic fatty liver disease: Interleukin-6-174G\/C polymorphism is associated with non-alcoholic steatohepatitis","volume":"41","author":"Carulli","year":"2009","journal-title":"Dig. Liver Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/hep.23759","article-title":"The association of genetic variability in PNPLA3 with histological severity of nonalcoholic fatty liver disease","volume":"52","author":"Rotman","year":"2010","journal-title":"Hepatology"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Taliento, A.E., Dallio, M., Federico, A., Prati, D., and Valenti, L. (2019). Novel insights into the genetic landscape of nonalcoholic fatty liver disease. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16152755"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: From new variants to the clinic","volume":"72","author":"Trepo","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.31032","article-title":"Patatin-like phospholipase domain-containing protein 3I148M and liver fat and fibrosis scores predict liver disease mortality in the, U.S. population","volume":"71","author":"Ruhl","year":"2020","journal-title":"Hepatology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","article-title":"PNPLA3 as a therapeutic target for fatty liver disease: The evidence to date","volume":"25","author":"Cherubini","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1194\/jlr.M048777","article-title":"The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: A meta-analysis","volume":"56","author":"Shen","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1210\/clinem\/dgaa729","article-title":"The PNPLA3-I148M variant confers an antiatherogenic lipid profile in insulin-resistant patients","volume":"106","author":"Luukkonen","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Huang, G., Wallace, D.F., Powell, E.E., Rahman, T., Clark, P.J., and Subramaniam, V.N. (2023). Gene variants implicated in steatotic liver disease: Opportunities for diagnostics and therapeutics. Biomedicines, 11.","DOI":"10.3390\/biomedicines11102809"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"101111","DOI":"10.1016\/j.molmet.2020.101111","article-title":"Genetic and epigenetic factors determining NAFLD risk","volume":"50","author":"Jonas","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/hep.22656","article-title":"Hepatic function is preserved in the absence of mature microRNAs","volume":"49","author":"Hand","year":"2009","journal-title":"Hepatology"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in control of gene expression: An overview of nuclear functions. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101712"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Ding, J., Li, M., Wan, X., Jin, X., Chen, S., and Yu, C. (2015). Effect of miR-34a in regulating steatosis by targeting PPAR\u03b1 expression in nonalcoholic fatty liver disease. Sci. Rep., 5.","DOI":"10.1038\/srep13729"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Erceg, S., Munjas, J., Sopic, M., Tamasevic, R., Mitrovic, M., Kotur-Stevuljevic, J., Mamic, M., Vujcic, S., Klisic, A., and Ninic, A. (2025). Expression Analysis of Circulating miR-21, miR-34a and miR-122 and Redox Status Markers in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients with and Without Type 2 Diabetes. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062392"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Hu, Y., Peng, X., Du, G., Zhang, Z., Zhai, Y., Xiong, X., and Luo, X. (2022). MicroRNA-122-5p inhibition improves inflammation and oxidative stress damage in dietary-induced non-alcoholic fatty liver disease through targeting FOXO3. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.803445"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Nonalcoholic fatty liver disease and risk of fatal and nonfatal cardiovascular events: An updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","article-title":"Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease","volume":"117","author":"Milligan","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"20420188221145549","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: A multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1116861","DOI":"10.3389\/fcvm.2023.1116861","article-title":"The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease","volume":"10","author":"Finney","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"E852","DOI":"10.1152\/ajpendo.00193.2019","article-title":"HDL flux is higher in patients with nonalcoholic fatty liver disease","volume":"317","author":"McCullough","year":"2019","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.amjcard.2017.07.107","article-title":"Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction","volume":"120","author":"Keskin","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cmet.2024.04.020","article-title":"Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periostin","volume":"36","author":"Xie","year":"2024","journal-title":"Cell Metab."},{"key":"ref_176","first-page":"196","article-title":"Association of non-alcoholic fatty liver disease with coronary artery calcification progression: A systematic review and meta-analysis","volume":"16","author":"Koulaouzidis","year":"2021","journal-title":"Prz. Gastroenterol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/ATVBAHA.122.318661","article-title":"Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease with coronary artery calcification: A cross-sectional and longitudinal cohort study","volume":"43","author":"Sung","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"101468","DOI":"10.1016\/j.diabet.2023.101468","article-title":"Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke","volume":"49","author":"Chen","year":"2023","journal-title":"Diabetes Metab."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"174304","DOI":"10.1016\/j.ejphar.2021.174304","article-title":"Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK\/mTOR pathway","volume":"907","author":"Luo","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4103\/jcrt.JCRT_963_19","article-title":"Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K\/AKT\/GSK-3\u03b2\/mTOR and Wnt\/\u03b2-catenin pathways; in vitro","volume":"17","author":"Thabet","year":"2021","journal-title":"J. Cancer Res. Ther."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Nasiri-Ansari, N., Nikolopoulou, C., Papoutsi, K., Kyrou, I., Mantzoros, C.S., Kyriakopoulos, G., Chatzigeorgiou, A., Kalotychou, V., Randeva, M.S., and Chatha, K. (2021). Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(-\/-) mice by activating autophagy and reducing ER stress and apoptosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020818"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.116.235069","article-title":"Empagliflozin protects against diet-induced NLRP3 inflammasome activation and lipid accumulation","volume":"359","author":"Benetti","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2018.03.043","article-title":"Canagliflozin protects against nonalcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation","volume":"828","author":"Kabil","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4254\/wjh.v4.i12.327","article-title":"Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment","volume":"4","author":"Paschos","year":"2012","journal-title":"World J. Hepatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"942753","DOI":"10.3389\/fcvm.2022.942753","article-title":"Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality","volume":"9","author":"Ng","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Peng, D., Yu, Z., Wang, M., Shi, J., Sun, L., Zhang, Y., Zhao, W., Chen, C., Tang, J., and Wang, C. (2022). Association of metabolic dysfunction-associated fatty liver disease with left ventricular diastolic function and cardiac morphology. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.935390"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13098-023-01102-0","article-title":"Metabolic dysfunction-associated fatty liver disease and incident heart failure risk: The Kailuan cohort study","volume":"15","author":"Wei","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e010841.201","DOI":"10.1161\/CIRCHEARTFAILURE.123.010841","article-title":"Sex and age differences in the association between metabolic dysfunction-associated fatty liver disease and heart failure: A prospective cohort study","volume":"17","author":"Wu","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: An updated meta-analysis of about 11 million individuals","volume":"72","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","article-title":"How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?","volume":"15","author":"Geng","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.hlc.2022.04.056","article-title":"Portopulmonary hypertension: A review of the current literature","volume":"31","author":"Peppas","year":"2022","journal-title":"Heart Lung Circ."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cld.2022.08.002","article-title":"Portopulmonary hypertension","volume":"27","author":"Lai","year":"2023","journal-title":"Clin. Liver Dis."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/17474124.2019.1587293","article-title":"An update on cirrhotic cardiomyopathy","volume":"13","author":"Danielsen","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Sonaglioni, A., Cerini, F., Fagiani, V., Nicolosi, G.L., Rumi, M.G., Lombardo, M., and Muti, P. (2025). Effect of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) on Left Ventricular Mechanics in Patients Without Overt Cardiac Disease: A Systematic Review and Meta-Analysis. J. Clin. Med., 14.","DOI":"10.37766\/inplasy2025.3.0037"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Lei, F., Qin, J.J., Song, X., Liu, Y.M., Chen, M.M., Sun, T., Huang, X., Deng, K.Q., Zuo, X., and Yao, D. (2022). The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1007171"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","article-title":"Association of MAFLD with end-stage kidney disease: A prospective study of 337,783 UK Biobank participants","volume":"17","author":"Chen","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5009\/gnl19069","article-title":"Extrahepatic manifestations of nonalcoholic hepatic steatosis","volume":"14","author":"Li","year":"2020","journal-title":"Gut Liver"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Gallo, G., Lanza, O., and Savoia, C. (2023). New insight in cardiorenal syndrome: From biomarkers to therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065089"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2022.05.030","article-title":"Liver stiffness, not fatty liver disease, is associated with atrial fibrillation: The Rotterdam Study","volume":"77","author":"Lu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_201","first-page":"21","article-title":"Noninvasive methods for assessing liver fibrosis and steatosis","volume":"20","author":"Kazi","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.numecd.2024.03.025","article-title":"Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease","volume":"34","author":"Shibata","year":"2024","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.numecd.2023.11.011","article-title":"Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: A population-based cohort study","volume":"34","author":"Ciardullo","year":"2024","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), and Asociaci\u00f3n Latinoamericana para el Estudio del H\u00edgado (ALEH) (2015). EASL\u2013ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol., 63, 237\u2013264.","DOI":"10.1016\/j.jhep.2015.04.006"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Ballestri, S., Mantovani, A., Baldelli, E., Lugari, S., Maurantonio, M., Nascimbeni, F., Marrazzo, A., Romagnoli, D., Targher, G., and Lonardo, A. (2021). Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics, 11.","DOI":"10.3390\/diagnostics11010098"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00261-019-02031-1","article-title":"Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: Single-center experience","volume":"44","author":"Alem","year":"2019","journal-title":"Abdom. Radiol."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Vidili, G., Arru, M., Meloni, P., Solinas, G., Atzori, S., and Maida, I. (2024). Comparison of 2D shear wave elastography and transient elastography in non-invasive evaluation of liver fibrosis in hepatitis C virus-related chronic liver disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13144061"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/1319-3767.153812","article-title":"Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis","volume":"21","author":"AlShaalan","year":"2015","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/nbm.3320","article-title":"MRS: A noninvasive window into cardiac metabolism","volume":"28","author":"Bekkers","year":"2015","journal-title":"NMR Biomed."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1093\/ehjci\/jeac175","article-title":"Pericoronary adipose tissue attenuation: Diagnostic and prognostic implications","volume":"23","author":"Kuneman","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Yuvaraj, J., Lin, A., Nerlekar, N., Munnur, R.K., Cameron, J.D., Dey, D., Nicholls, S.J., and Wong, D.T.L. (2021). Pericoronary adipose tissue attenuation is associated with high-risk plaque and subsequent acute coronary syndrome in patients with stable coronary artery disease. Cells, 10.","DOI":"10.3390\/cells10051143"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/HEP.0000000000001223","article-title":"Revealing new biomarker to predict MASLD progression","volume":"81","author":"Kanagalingam","year":"2025","journal-title":"Hepatology."},{"key":"ref_218","first-page":"24","article-title":"The Use of Non-i nvasive Biomarkers to Screen for Advanced Fibrosis Associated with Metabolic Dysfunction-associated Steatotic Liver Disease in People with Type 2 Diabetes: A Narrative Review","volume":"21","author":"Williams","year":"2025","journal-title":"Eur. Endocrinol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1038\/s41467-024-48956-0","article-title":"Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD","volume":"15","author":"Verschuren","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"102577","DOI":"10.1016\/j.pmedr.2023.102577","article-title":"Lifestyle factors affecting new-onset nonalcoholic fatty liver disease","volume":"37","author":"Takahata","year":"2024","journal-title":"Prev. Med. Rep."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Niederseer, D., Wernly, B., Aigner, E., Stickel, F., and Datz, C. (2021). NAFLD and cardiovascular diseases: Epidemiological, mechanistic and therapeutic considerations. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030467"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"2050312117745223","DOI":"10.1177\/2050312117745223","article-title":"Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"6","author":"Shirazinia","year":"2018","journal-title":"SAGE Open Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4254\/wjh.v11.i2.138","article-title":"Bariatric surgery in patients with non-alcoholic fatty liver disease\u2014From pathophysiology to clinical effects","volume":"11","author":"Laursen","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., and Guo, J. (2023). Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1087260"},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Brandt, A., Hern\u00e1ndez-Arriaga, A., Kehm, R., S\u00e1nchez, V., Jin, C.J., Nier, A., and Bergheim, I. (2019). Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-43228-0"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/dom.14263","article-title":"Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-link study","volume":"23","author":"Komorizono","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1871530321666210225110140","article-title":"Effects of metformin-single therapy on the level of inflammatory markers in serum of non-obese T2DM patients with NAFLD","volume":"22","author":"Mitrovic","year":"2022","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_230","first-page":"108984","article-title":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: Clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res","volume":"178","author":"Russo","year":"2021","journal-title":"Clin. Pract."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/dom.14319","article-title":"Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: Exenda, a 24-week, prospective, randomized, placebo-controlled pilot trial","volume":"23","author":"Harreiter","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.bjp.0707452","article-title":"Thiazolidinediones: Effects on insulin resistance and the cardiovascular system","volume":"153","author":"Quinn","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"108998","DOI":"10.1016\/j.jdiacomp.2025.108998","article-title":"Comparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis","volume":"39","author":"Lingyan","year":"2025","journal-title":"J. Diabetes Complicat."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"175322","DOI":"10.1016\/j.ejphar.2022.175322","article-title":"Novel dual PPAR-\u03b1\/\u03b3 agonists protect against liver steatosis and improve insulin sensitivity while avoiding side effects","volume":"935","author":"Guru","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/s41401-024-01389-3","article-title":"SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization","volume":"45","author":"Lin","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empagliflozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","volume":"498","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"bqab157","DOI":"10.1210\/endocr\/bqab157","article-title":"SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD","volume":"162","author":"Ala","year":"2021","journal-title":"Endocrinology"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"107492","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Yoshioka, N., Tanaka, M., Ochi, K., Watanabe, A., Ono, K., Sawada, M., Ogi, T., Itoh, M., Ito, A., and Shiraki, Y. (2021). The sodium-glucose cotransporter-2 inhibitor tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model. Biomed. Pharmacother., 140.","DOI":"10.1016\/j.biopha.2021.111738"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"108558","DOI":"10.1016\/j.jdiacomp.2023.108558","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials","volume":"37","author":"Jin","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pcd.2024.03.005","article-title":"Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis. Prim","volume":"18","author":"Fang","year":"2024","journal-title":"Care Diabetes"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Mao, T., Zhang, C., Yang, S., Bi, Y., Li, M., and Yu, J. (2024). Semaglutide alters gut microbiota and improves NAFLD in db\/db mice. Biochem. Biophys. Res. Commun., 710.","DOI":"10.1016\/j.bbrc.2024.149882"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"622589","DOI":"10.3389\/fendo.2020.622589","article-title":"Comparison of the efficacy of glucagon-like peptide-1 receptor agonists in patients with metabolic associated fatty liver disease: Updated systematic review and meta-analysis","volume":"11","author":"Dai","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbadis.2014.02.004","article-title":"FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model","volume":"1842","author":"Kunne","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"e00163","DOI":"10.1002\/edm2.163","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review","volume":"3","author":"Lv","year":"2020","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","article-title":"Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: A narrative review","volume":"37","author":"Ballestri","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.pharmr.2024.100018","article-title":"Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options","volume":"77","author":"Zhang","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: Current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: A systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00535-010-0291-8","article-title":"Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease","volume":"46","author":"Park","year":"2011","journal-title":"J. Gastroenterol."},{"key":"ref_258","first-page":"1199","article-title":"The role of PCSK9 in NAFLD\/NASH and therapeutic implications of PCSK9 inhibition. Expert Rev","volume":"15","author":"Banach","year":"2022","journal-title":"Clin. Pharmacol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bcp.14943","article-title":"Statin liver safety in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"88","author":"Pastori","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/HYPERTENSIONAHA.119.13419","article-title":"Nonalcoholic fatty liver disease: An emerging driver of hypertension","volume":"75","author":"Zhao","year":"2020","journal-title":"Hypertension"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/jgh.12643","article-title":"Clinical association between non-alcoholic fatty liver disease and the development of hypertension","volume":"29","author":"Ryoo","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/HJH.0000000000000532","article-title":"Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk","volume":"33","author":"Aneni","year":"2015","journal-title":"J. Hypertens."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"24155","DOI":"10.18632\/oncotarget.23816","article-title":"Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/8081\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:32:42Z","timestamp":1760034762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/8081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":264,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26168081"],"URL":"https:\/\/doi.org\/10.3390\/ijms26168081","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}